Furthermore, genomic analysis of NB patients showed that high ADRB3 expression, compared to the low expression group, was correlated with worse clinical outcomes and that ADRB3 expression affected different immune-related pathways [261]. The gene discussed is ADRB3; the disease is neuroblastoma.